Nuvalent (NASDAQ:NUVL) CEO James Richard Porter Sells 9,543 Shares

Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter sold 9,543 shares of Nuvalent stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $97.16, for a total transaction of $927,197.88. Following the sale, the chief executive officer owned 278,629 shares in the company, valued at approximately $27,071,593.64. This represents a 3.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

James Richard Porter also recently made the following trade(s):

• On Monday, January 5th, James Richard Porter sold 17,890 shares of Nuvalent stock. The shares were sold at an average price of $97.32, for a total transaction of $1,741,054.80.
• On Thursday, October 16th, James Richard Porter sold 27,000 shares of Nuvalent stock. The shares were sold at an average price of $90.63, for a total value of $2,447,010.00.

Nuvalent Stock Performance

Shares of NASDAQ NUVL traded up $9.62 during mid-day trading on Wednesday, reaching $106.82. The company had a trading volume of 895,694 shares, compared to its average volume of 779,373. The company has a market capitalization of $7.77 billion, a price-to-earnings ratio of -20.08 and a beta of 1.32. The stock has a fifty day moving average of $102.57 and a two-hundred day moving average of $88.78. Nuvalent, Inc. has a 12-month low of $55.53 and a 12-month high of $112.88.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same quarter in the previous year, the business posted ($1.28) EPS. Sell-side analysts forecast that Nuvalent, Inc. will post -3.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on NUVL shares. HC Wainwright boosted their target price on Nuvalent from $130.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Cantor Fitzgerald initiated coverage on Nuvalent in a research note on Wednesday, October 15th. They issued an “overweight” rating and a $135.00 price target for the company. Stifel Nicolaus lifted their price objective on shares of Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Canaccord Genuity Group assumed coverage on Nuvalent in a research report on Wednesday, November 12th. They issued a “buy” rating and a $126.00 price target for the company. Finally, UBS Group reiterated a “buy” rating on shares of Nuvalent in a research note on Wednesday, December 17th. Fifteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Nuvalent currently has a consensus rating of “Moderate Buy” and an average target price of $138.33.

Hedge Funds Weigh In On Nuvalent

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Nuvalent by 1.8% during the third quarter. Vanguard Group Inc. now owns 4,605,007 shares of the company’s stock worth $398,241,000 after acquiring an additional 80,883 shares during the period. Wellington Management Group LLP raised its stake in shares of Nuvalent by 46.0% in the third quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after purchasing an additional 724,491 shares in the last quarter. State Street Corp lifted its position in Nuvalent by 4.2% in the second quarter. State Street Corp now owns 1,490,279 shares of the company’s stock worth $113,708,000 after purchasing an additional 59,620 shares during the period. Commodore Capital LP increased its holdings in Nuvalent by 1.8% in the 3rd quarter. Commodore Capital LP now owns 1,400,000 shares of the company’s stock valued at $121,072,000 after buying an additional 25,000 shares during the period. Finally, RA Capital Management L.P. acquired a new position in shares of Nuvalent in the 3rd quarter valued at $107,794,000. 97.26% of the stock is currently owned by institutional investors.

Key Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James Richard Porter sold 9,543 shares on Jan. 6 at an average $97.16 (≈ $927.2k); his post-sale holding was 278,629 shares (3.31% ownership drop). SEC Filing
• Negative Sentiment: CEO James Richard Porter sold 17,890 shares on Jan. 5 at an average $97.32 (≈ $1.74M); post-sale direct ownership 288,172 shares (5.85% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 81,733 shares (3.75% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 84,914 shares (4.75% ownership drop). SEC Filing
• Negative Sentiment: Insider Christopher Durant Turner sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 55,130 shares (5.46% ownership drop). SEC Filing
• Negative Sentiment: Christopher Durant Turner sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 58,311 shares (6.77% ownership drop). SEC Filing
• Negative Sentiment: Insider Deborah Ann Miller sold 2,589 shares on Jan. 6 at $97.16 (≈ $251.5k); post-sale holding 42,134 shares (5.79% ownership drop). SEC Filing
• Negative Sentiment: Deborah Ann Miller sold 4,363 shares on Jan. 5 at $97.32 (≈ $424.6k); post-sale holding 44,723 shares (8.89% ownership drop). SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,664 shares on Jan. 6 at $97.17 (≈ $258.9k); post-sale holding 65,888 shares (3.89% ownership drop). SEC Filing
• Negative Sentiment: Henry E. Pelish sold 2,496 shares on Jan. 5 at $97.32 (≈ $242.9k); post-sale holding 68,552 shares (3.51% ownership drop). SEC Filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.